Last reviewed · How we verify
Naftin Cream
At a glance
| Generic name | Naftin Cream |
|---|---|
| Sponsor | Merz North America, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis (PHASE1)
- BE Study of Naftifine HCL (PHASE3)
- Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis (PHASE1)
- Pediatric Subjects With Tinea Corporis (PHASE4)
- An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis (PHASE4)
- Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris (PHASE3)
- Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis (PHASE1)
- Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naftin Cream CI brief — competitive landscape report
- Naftin Cream updates RSS · CI watch RSS
- Merz North America, Inc. portfolio CI